| Protocols | ||
|---|---|---|
| 2 protocol(s) meet the specified criteria | ||
| Drug: BAY 43-9006 | ||
| Protocol No. | Title | Status |
| AAML1031 | A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD | Open |
| XL184-312 | A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | Open |